Thursday, March 14, 2019 1:59:53 AM
To begin with, I believe our price would almost immediately reach $.10 to $.25, if they determined they needed $50 million, worst case they'd approach their authorized share limit, but if they waited for patent approvals, they could do far better than that.
By next year, with a few patent approvals and drugs in Phase 2 trials with efficacy demonstrated, I believe a market cap between $.5 and $1 billion is very possible, even with full dilution our share price would be somewhere in the $1 to $2 range. At that point a 1 for 2 or 3 reverse split would bring the price to striking distance of the Nasdaq, if not over the top, and would bring the share count to the point that substantial room of growth again existed.
Of course if the good news was better, fewer share would be needed for funding, and the numbers would only get better. Of course the opposite is true as well, if no patents are approved, or efficacy isn't seen in our drugs in trials, we could be bankrupt. The reality is, that worst case scenario is true whether a R/S is done or not, success requires gaining the intellectual property rights and proving they work. I simply don't believe that with 150 million shares currently outstanding it requires taking that number down to 1.5 million shares or less. If they were speaking about bringing the shares down to 50 million, it could be a figure worth considering, but I'd still suggest they gain share price by getting things done first.
Gary
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM